Wellington Management
Wellington Management focuses on investment management by applying its full resources to meet the needs of institutional clients they serve.
Business Model:
Revenue: $1B
Employees: 501-1,000
Rankings
Detailed Wellington Management Information
Geographic Data
Address: 280 Congress Street
City: Boston
State: MA
Zip: 02210
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
397,658Website Global Rank
133,802Website Monthly Traffic
Twitter Followers
Description
Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span the global equity, fixed income, currency, commodity, and alternatives markets. They also offer asset allocation, multi-manager, and specialty approaches. It was founded in 1928 and headquartered in Boston, Massachusetts.
Contact Phone:
+16179515000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2021 | JUSPAY | Series C | 60M |
| 10/2020 | Lordstown Motors | Post-IPO Equity | 500M |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 8/2018 | Slack | Series H | 427M |
| 7/2017 | WeWork China | Series A | 0 |
| 2/2014 | nCino | Series B | 11M |
| 6/2017 | Nightstar Therapeutics | Series C | 45M |
| 1/2022 | CodeSee | Seed | 7M |
| 12/2019 | Impulse Dynamics | Series D | 0 |
| 4/2014 | Pure Storage | Series F | 225M |
| 3/2015 | Zuora | Series F | 0 |
| 10/2014 | Fintiv | Series B | 185M |
| 11/2021 | Faire | Series G | 0 |
| 6/2021 | Payoneer | PIPE | 300M |
| 1/2022 | Creditas | Series F | 0 |
| 8/2017 | Atreca | Series B | 35M |
| 9/2018 | Atreca | Series C | 125M |
| 3/2021 | Zenas BioPharma | Series A | - |
| 8/2016 | Compass | Series D | 75M |
| 10/2009 | neoSaej | Venture Round | 1.7M |
| 4/2014 | Apigee | Venture Round | 0 |
| 6/2021 | Perella Weinberg Partners | Post-IPO Equity | 125M |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 6/2022 | Kinside | Series A | 0 |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 8/2021 | Trove | Series D | 77.5M |
| 10/2020 | LianBio | Series A | 0 |
| 2/2015 | Invuity | Equity | 22.9M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | Olema Oncology | Series B | 54M |
| 11/2017 | HeartFlow | Series E | 0 |
| 6/2020 | Freeline | Series C | 80M |
| 3/2022 | Span.IO | Series B | 0 |
| 12/2022 | Dataiku | Series F | 200M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 4/2023 | HeartFlow | Series F | 0 |
| 11/2014 | Powa | Series C | 80M |
| 6/2017 | Houzz | Series E | 400M |
| 1/2017 | Neon Therapeutics | Series B | 70M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 9/2020 | Novellus | Series C | 57M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 7/2022 | Meati Foods | Series C | 0 |
| 6/2021 | Lendbuzz | Series C | 0 |
| 5/2014 | Datalogix | Series C | 45M |
| 3/2020 | JUSPAY | Series B | 21.6M |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 4/2021 | Urban Company | Series F | 188M |
| 4/2021 | Swiggy | Series J | 0 |
| 9/2016 | DEFY Media | Series B | 70M |
| 6/2019 | Omada Health | Series D | 73M |
| 9/2020 | Affirm | Series G | 500M |
| 4/2019 | Prove (formerly Payfone) | Series G | 15.1M |
| 11/2017 | Tricida | Series D | 0 |
| 2/2016 | Magic Leap | Series C | 793.5M |
| 1/2021 | Affinivax | Series C | 226M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 3/2021 | Paidy | Series D | 0 |
| 9/2022 | RayzeBio | Series D | 160M |
| 4/2015 | Rethink Robotics | Series D | 13.4M |
| 4/2021 | Current | Series D | 220M |
| 1/2015 | Global Blood Therapeutics | Series B | 48M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2021 | BetterUp | Series E | 0 |
| 8/2015 | Payoneer | Series E | 50M |
| 7/2021 | Blackbuck | Series E | 0 |
| 5/2017 | Peloton | Series E | 0 |
| 8/2014 | The Honest Company | Series C | 70M |
| 9/2021 | SpotOn | Series E | 300M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 3/2015 | Birst | Series F | 65M |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 5/2015 | MarkLogic | Series F | 102M |
| 7/2000 | SensAble Technologies | Series C | 23M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 12/2020 | Cityblock Health | Series C | 160M |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 10/2019 | Current | Series B | 31.2M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 8/2020 | Synthego | Series D | 100M |
| 11/2022 | AMP Robotics | Series C | 0 |
| 6/2018 | ezCater | Series D | 100M |
| 5/2023 | Quince | Series B | 0 |
| 4/2021 | Patreon | Series F | 155M |
| 4/2015 | Warby Parker | Series D | 100M |
| 9/2020 | Attentive | Series D | 230M |
| 3/2021 | Cityblock Health | Series C | 192M |
| 8/2014 | Pure Storage | Secondary Market | 60M |
| 1/2022 | Dave | Post-IPO Equity | 0 |
| 12/2014 | Redfin | Series G | 71M |
| 9/2020 | Skillz | Post-IPO Equity | 0 |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 6/2020 | Goldfinch Biopharma | Series B | 100M |
| 9/2020 | Patreon | Series E | 90M |
| 9/2015 | General Assembly | Series D | 70M |
| 3/2023 | Span.IO | Series B | 0 |
| 7/2021 | Markforged | Post-IPO Equity | 0 |
| 12/2021 | ROKT | Series E | 325M |
| 1/2020 | Generation Bio | Series C | 110M |
| 11/2022 | MBX Biosciences | Series B | 115M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 4/2021 | Greenlight | Series D | 260M |
| 6/2021 | Latch | Post-IPO Equity | 190M |
| 2/2021 | Butterfly Network | Post-IPO Equity | 175M |
| 6/2015 | Harry&s;s | Series C | 97.5M |
| 9/2015 | Rubicon | Series C | 57.1M |
| 10/2014 | Invitae | Series F | 0 |
| 6/2015 | Airbnb | Series E | 1.5B |
| 10/2018 | Coinbase | Series E | 300M |
| 4/2019 | Affirm | Series F | 300M |
| 4/2023 | Clerkie | Series A | 0 |
| 4/2019 | ezCater | Series D | 150M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 6/2021 | Faire | Series F | 260M |
| 10/2020 | Scopely | Series E | 340M |
| 5/2015 | DocuSign | Series F | 0 |
| 6/2015 | TabbedOut | Series C | 21.5M |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2023 | Upstream Bio | Series B | 0 |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 6/2014 | Uber | Series D | 1.4B |
| 9/2021 | Arcadia | Series D | 0 |
| 8/2014 | Lookout | Series F | 150M |
| 6/2022 | Guild Education | Series F | 0 |
| 10/2017 | Forty Seven | Series B | 75M |
| 2/2017 | Fuze, an 8x8 company | Series E | 104M |
| 9/2018 | PagerDuty | Series D | 90M |
| 6/2020 | Prove (formerly Payfone) | Series H | 98M |
| 8/2018 | Peloton | Series F | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 7/2020 | VelosBio | Series B | 137M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 2/2022 | Somatus | Series E | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 5/2022 | Arcadia | Series E | 0 |
| 2/2015 | nCino | Series B | 29M |
| 1/2015 | SoFi | Series D | 213M |
| 11/2017 | Compass | Series E | 0 |
| 5/2021 | Snapdocs | Series D | 150M |
| 11/2019 | ACV | Series E | 150M |
| 12/2021 | Anchorage Digital | Series D | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 9/2015 | SoFi | Series E | 1B |
| 10/2017 | PolicyBazaar | Series E | 77M |
| 2/2020 | Swiggy | Series I | 113M |
| 3/2016 | The Trade Desk | Series C | 60M |
| 1/2016 | ForeScout Technologies | Series G | 80M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 6/2023 | Caraway | Series A | 0 |
| 9/2021 | Archaea Energy | Post-IPO Equity | 0 |
| 1/2021 | Billtrust | Post-IPO Equity | 200M |
| 8/2013 | Powa | Series A | 76M |
| 5/2016 | Speakaboos | Series B | 12.5M |
| 3/2015 | Nanigans | Series B | 24M |
| 12/2014 | Coupang | Private Equity Round | 300M |
| 7/2022 | Moving Analytics | Series A | 0 |
| 12/2020 | Creditas | Series E | 255M |
| 4/2014 | New Relic | Private Equity Round | 100M |
| 1/2022 | Digit Insurance | Venture Round | 70M |
| 7/2021 | Hyzon Motors | Post-IPO Equity | 0 |
| 3/2021 | Arrival | Post-IPO Equity | 400M |
| 12/2020 | Porch Group | Post-IPO Equity | 150M |
| 8/2014 | Nutanix | Series E | 140M |
| 5/2019 | Away | Series D | 100M |
| 7/2016 | Sprinklr | Series F | 105M |
| 4/2021 | Greenlight | Series D | 260M |
| 6/2021 | ironSource | Post-IPO Equity | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 10/2014 | WeWork | Series D | 355M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 11/2020 | Current | Series C | 131M |
| 10/2014 | GreenSky | Private Equity Round | 350M |
| 4/2021 | Scale AI | Series E | 325M |
| 8/2022 | SeatGeek | Series E | 238M |
| 5/2015 | Series G | 186M | |
| 7/2021 | Thriveworks | Venture Round | - |
| 12/2022 | ROKT | Secondary Market | - |
| 10/2018 | Tanium | Private Equity Round | 200M |
| 12/2017 | Neon Therapeutics | Series B | 36M |
| 2/2022 | Omada Health | Series E | 0 |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 1/2021 | PPRO | Private Equity Round | 180M |
| 5/2021 | Oxford Nanopore Technologies | Venture Round | 270.8M |
| 8/2015 | The Honest Company | Series D | 100M |
| 5/2014 | Malauzai Software | Series C | 6.5M |
| 7/2021 | Sundae | Series C | 0 |
| 5/2016 | BEGiN | Series B | 0 |
| 3/2015 | Dataminr | Series D | 130M |
| 9/2014 | Veracode | Series F | 40M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 12/2021 | Course Hero | Series C | 380M |
| 12/2021 | Olist | Series E | 186M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 7/2021 | Lucid Motors | Post-IPO Equity | 0 |
| 7/2021 | EVgo | Post-IPO Equity | 400M |
| 8/2015 | Klarna | Secondary Market | 80M |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 9/2022 | flavrs | Seed Round | 0 |
| 4/2015 | Voyager Therapeutics | Series B | 0 |
| 4/2015 | Sharecare | Venture Round | 0 |
| 4/2000 | Optical Switch | Venture Round | 0 |
| 11/2018 | Auris Health | Series E | 0 |
| 4/2015 | Oscar Health | Series C | 145M |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 6/2020 | Verve Therapeutics | Series A | 63M |
| 6/2022 | FalconX | Series D | 0 |
| 12/2018 | Swiggy | Series H | 1B |
| 7/2022 | Meati Foods | Series C | 0 |
| 7/2022 | Moving Analytics | Series A | 0 |
| 6/2022 | FalconX | Series D | 0 |
| 6/2022 | Kinside | Series A | 0 |
| 6/2022 | Guild Education | Series F | 0 |
| 5/2022 | Arcadia | Series E | 0 |
| 3/2022 | Span.IO | Series B | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Somatus | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
